Aripiprazole

Generic Name
Aripiprazole
Brand Names
Abilify, Aripiprazole Mylan Pharma (previously Aripiprazole Pharmathen), Abilify Maintena, Aripiprazole Accord, Aripiprazole Sandoz, Aripiprazole Zentiva
Drug Type
Small Molecule
Chemical Formula
C23H27Cl2N3O2
CAS Number
129722-12-9
Unique Ingredient Identifier
82VFR53I78
Background

Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects through agonism of dopaminergic and 5-HT1A ...

Indication

Aripiprazole is indicated for the treatment of acute manic and mixed episodes associated with bipolar I disorder, irritability associated with autism spectrum disorder, schizophrenia, and Tourette's disorder. It is also used as an adjunctive treatment of major depressive disorder.[L45859 An injectable formulation of aripiprazole is indicated for agitation as...

Associated Conditions
Agitation, Bipolar 1 Disorder, Irritability, Major Depressive Disorder (MDD), Mixed manic depressive episode, Psychosis, Psychotic Depression, Schizophrenia, Tourette's Disorder (TD), Acute Manic episode
Associated Therapies
Monotherapy
Clinical Trials
Related News

Atypical Antipsychotic-induced Mitochondrial Dysfunction in Patients With Schizophrenia

Phase 4
Recruiting
Conditions
Schizophrenia
Interventions
Drug: Aripiprazole
Drug: Risperidone
First Posted Date
2024-02-01
Last Posted Date
2024-12-19
Lead Sponsor
All India Institute of Medical Sciences, Bhubaneswar
Target Recruit Count
60
Registration Number
NCT06236451
Locations
🇮🇳

All India Institute of Medical Sciences (AIIMS), Bhubaneswar, Odisha, India

Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis

First Posted Date
2023-09-29
Last Posted Date
2023-09-29
Lead Sponsor
Consorcio Centro de Investigación Biomédica en Red (CIBER)
Target Recruit Count
244
Registration Number
NCT06060886

Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD)

First Posted Date
2023-04-18
Last Posted Date
2023-08-14
Lead Sponsor
First Affiliated Hospital of Chongqing Medical University
Target Recruit Count
520
Registration Number
NCT05814640
Locations
🇨🇳

The First Affiliated Hospital of Chongqing Medical University, Chongqing, Province, China

VA Aripiprazole vs Esketamine for Treatment Resistant Depression

First Posted Date
2022-09-26
Last Posted Date
2024-01-05
Lead Sponsor
VA Office of Research and Development
Registration Number
NCT05554627
Locations
🇺🇸

Central Arkansas VHS John L. McClellan Memorial Veterans Hospital, Little Rock, AR, Little Rock, Arkansas, United States

🇺🇸

New Mexico VA Health Care System, Albuquerque, NM, Albuquerque, New Mexico, United States

🇺🇸

Edward Hines Jr. VA Hospital, Hines, IL, Hines, Illinois, United States

and more 23 locations

Aripiprazole in Body Focused Repetitive Behaviors

First Posted Date
2022-09-19
Last Posted Date
2024-08-01
Lead Sponsor
University of Chicago
Target Recruit Count
100
Registration Number
NCT05545891
Locations
🇺🇸

University of Chicago, Chicago, Illinois, United States

The Impact of Aripiprazole Long-acting on Myelin and Cognition in the Onset of Schizophrenia

First Posted Date
2022-04-11
Last Posted Date
2022-04-22
Lead Sponsor
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Target Recruit Count
15
Registration Number
NCT05322031
Locations
🇮🇹

Prof. Paolo Brambilla, Milan, Italy

Atypical Antipsychotics Influence on the Safety of the Heart and Monitoring Indicators Model Building

First Posted Date
2020-06-24
Last Posted Date
2020-08-26
Lead Sponsor
Shanghai Mental Health Center
Target Recruit Count
350
Registration Number
NCT04446234
Locations
🇨🇳

CHINA, Shanghai, Minhang, China

A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder

Phase 1
Completed
Conditions
Schizophrenia
Bipolar I Disorder
Interventions
Drug: Aripiprazole
First Posted Date
2019-07-23
Last Posted Date
2023-11-18
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
266
Registration Number
NCT04030143
Locations
🇺🇸

NRC Research Institute, Orange, California, United States

🇺🇸

California Clinical Trials Medical Group, Glendale, California, United States

🇺🇸

Woodland International Research Group, Rogers, Arkansas, United States

and more 15 locations

Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 3-years Follow-up

First Posted Date
2019-03-20
Last Posted Date
2020-01-14
Lead Sponsor
Fundación Marques de Valdecilla
Target Recruit Count
115
Registration Number
NCT03883204
Locations
🇪🇸

University Hospital Marques de Valdecilla, Santander, Cantabria, Spain

Safety and Efficacy of Brexpiprazole in the Treatment of Schizophrenia

Phase 3
Completed
Conditions
Schizophrenia
Interventions
Drug: Brexpiprazole
Drug: Aripiprazole
First Posted Date
2019-03-14
Last Posted Date
2021-11-12
Lead Sponsor
Otsuka Beijing Research Institute
Target Recruit Count
371
Registration Number
NCT03874494
Locations
🇨🇳

No.15 Yanyin Road, Yanta District, Xi'an, Shanxi, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy